Table 1.

Baseline Characteristics of DLBCL Patients Treated With R-CHOP (N = 481).

Variable	Proportion
ECOG > 2	2.50%
IPI > 2	42.41%
Raised LDH	61.54%
Ann Arbor stage > II	60.50%
Median age	65.7 y
Number of extranodal > 1	17.88%
ABC subtype	27.86%
GCB subtype	48.02%
Unclassified subtype	17.67%
MHG subtype	6.44%

ABC = activated B-cell–like; DLBCL = diffuse large B-cell lymphoma; ECOG = Eastern Cooperative Oncology Group; IPI = International Prognostic Index; LDH = lactate dehydrogenase; MHG = molecular high-grade; R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.